Ensign Peak Advisors
ABBV icon

Ensign Peak Advisors’s AbbVie ABBV Stock Holding History

Ensign Peak Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$217M Sell
861,436
-365,434
-30% -$78.6M 0.36% 51
2026
Q1 		$267M Sell
1,226,870
-786,118
-39% -$174M 0.5% 37
2025
Q4 		$460M Sell
2,012,988
-31,575
-2% -$7.19M 0.81% 17
2025
Q3 		$473M Sell
2,044,563
-109,443
-5% -$22.3M 0.78% 18
2025
Q2 		$400M Buy
2,154,006
+31,590
+1% +$5.87M 0.68% 21
2025
Q1 		$445M Buy
2,122,416
+63,027
+3% +$12.3M 0.85% 18
2024
Q4 		$366M Buy
2,059,389
+29,697
+1% +$5.46M 0.65% 25
2024
Q3 		$401M Sell
2,029,692
-44,209
-2% -$8.25M 0.7% 23
2024
Q2 		$356M Sell
2,073,901
-28,733
-1% -$4.76M 0.65% 27
2024
Q1 		$383M Buy
2,102,634
+127,034
+6% +$21.9M 0.7% 22
2023
Q4 		$306M Sell
1,975,600
-360,985
-15% -$52.6M 0.61% 34
2023
Q3 		$348M Buy
2,336,585
+525,155
+29% +$77.1M 0.74% 26
2023
Q2 		$244M Sell
1,811,430
-727,009
-29% -$107M 0.49% 48
2023
Q1 		$405M Sell
2,538,439
-331,094
-12% -$50.6M 0.88% 19
2022
Q4 		$464M Buy
2,869,533
+35,399
+1% +$5.43M 1.04% 13
2022
Q3 		$380M Sell
2,834,134
-842,306
-23% -$121M 0.94% 18
2022
Q2 		$563M Buy
3,676,440
+326,206
+10% +$49.8M 1.34% 8
2022
Q1 		$543M Buy
3,350,234
+623,629
+23% +$90.6M 1.1% 11
2021
Q4 		$369M Buy
2,726,605
+474,301
+21% +$56M 0.71% 25
2021
Q3 		$243M Buy
2,252,304
+530,612
+31% +$60.6M 0.51% 41
2021
Q2 		$194M Buy
1,721,692
+107,162
+7% +$12.1M 0.39% 70
2021
Q1 		$175M Buy
1,614,530
+56,783
+4% +$6.07M 0.38% 72
2020
Q4 		$167M Buy
1,557,747
+701,069
+82% +$67.4M 0.38% 62
2020
Q3 		$75M Buy
856,678
+156,569
+22% +$14.7M 0.19% 104
2020
Q2 		$68.7M Buy
700,109
+322,921
+86% +$28.4M 0.19% 100
2020
Q1 		$28.7M Sell
377,188
-102,289
-21% -$8.71M 0.1% 161
2019
Q4 		$42.5M Buy
+479,477
New +$39.8M 0.11% 151

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Ensign Peak Advisors's ABBV Position: Q2 2026 in Review

Ensign Peak Advisors reduced its AbbVie (ABBV) stake by 30% in Q2 2026, selling an estimated $78.6M and leaving 861,436 shares worth $217M. The position accounts for 0.36% of the portfolio, ranked #51.

Ensign Peak Advisors first reported a position in ABBV in Q4 2019 and has held it in 27 quarters since. The position peaked at $563M in Q2 2022. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Ensign Peak Advisors held 861,436 shares of AbbVie worth $217M as of Q2 2026.
  • Ensign Peak Advisors sold 365,434 AbbVie shares in Q2 2026, an estimated $78.6M.
  • AbbVie made up 0.36% of Ensign Peak Advisors's portfolio in Q2 2026, its #51 holding.
  • Ensign Peak Advisors first reported a position in AbbVie in Q4 2019 and has held it in 27 quarters since.
  • Ensign Peak Advisors's AbbVie position peaked at $563M in Q2 2022.
  • 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.